Zobrazeno 1 - 10
of 347
pro vyhledávání: '"Bucindolol"'
Autor:
Michiel Rienstra, Debra Marshall, William T. Abraham, Michel White, Ian A. Carroll, Sophia P. Huebler, Ryan Aleong, Dirk J. van Veldhuisen, Stephen B. Wilton, William H. Sauer, Stuart J. Connolly, Jonathan P. Piccini, Inder S. Anand, Christopher M. O'Connor, Jeff S. Healey, Christopher Dufton, Michael R. Bristow
Publikováno v:
Heart rhythm O2, 3(1), 40-49
Background: Heart failure (HF) patients with atrial fibrillation (AF) often have conduction system disorders, which may be worsened by β-blocker therapy.Objective: In a post hoc analysis we examined the prevalence of bradycardia and its association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c86dcdd227d41b4d3c403bd96061ea
https://doi.org/10.1016/j.hroo.2021.11.005
https://doi.org/10.1016/j.hroo.2021.11.005
Autor:
Gerasimos Filippatos, Brandon George, Kalliopi Keramida, Charity J. Morgan, Gaurav Choudhary, Neha Gupta, Ami E. Iskandrian, Wen-Chih Wu, Prakash Deedwania, Ali Ahmed, Gregg C. Fonarow, John G.F. Cleland, Charles Faselis, Phillip H. Lam
Publikováno v:
Journal of Cardiac Failure. 28:65-70
Background A low right ventricular ejection fraction (RVEF) is a marker of poor outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Beta-blockers improve outcomes in HFrEF, but whether this effect is modified by RVEF is un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fda22387731f113f4ba700fd30d52f4
https://doi.org/10.1016/j.cardfail.2021.07.026
https://doi.org/10.1016/j.cardfail.2021.07.026
Autor:
Sayuri Guro, Hiromi Sato, Ryota Takaoka, Hiroshi Suzuki, Akihiro Hisaka, Yukako Soejima, Hideki Yoshioka
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1081-1091 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
To characterize and compare various medicines for chronic heart failure (CHF), changes in circulatory physiological parameter during pharmacotherapy were investigated by a model‐based meta‐analysis (MBMA) of circulatory physiology. The clinical d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4060c82e2b816144004f3d8e9dbfb1c
https://doaj.org/article/e69ac8b1d47b40f3a7eae2a0230d78a9
https://doaj.org/article/e69ac8b1d47b40f3a7eae2a0230d78a9
Autor:
Jonathan P. Piccini, Christopher Dufton, Ian A. Carroll, Jeff S. Healey, William T. Abraham, Yaariv Khaykin, Ryan Aleong, Steven K. Krueger, William H. Sauer, Stephen B. Wilton, Michiel Rienstra, Dirk J. van Veldhuisen, Inder S. Anand, Michel White, A. John Camm, Paul D. Ziegler, Debra Marshall, Michael R. Bristow, Stuart J. Connolly, F Ayala-Paredes, A Bakbak, ML Bernier, DH Birnie, B Coutu, E Crystal, MW Deyell, KM Dyrda, MC Hartleib, ZW Laksman, P Leong-Sit, CA Morillo, AS Pandey, F Philippon, S Vizel, P Andréka, Z Csanadi, GZ Duray, T Forster, G Kerkovits, B Merkely, AC Nagy, T Simor, D Czarnecka, JD Kasprzak, WJ Musial, G Raczak, J Szachniewicz, JK Wranicz, S Apostolović, S Hinić, V Miloradović, D Simić, GJ Milhous, A Oomen, TJ Romer, LM van Vijk, PB Adamson, JD Allred, N Amjadi, MM Bahu, AJ Bank, AE Berman, MA Bernabei, RS Bhagwat, L Borgatta, AJ Buda, RT Cole, JL Collier, SJ Compton, O Costantini, MR Costanzo, IM Dauber, MP Donahue, I Dor, GF Egnacyzk, EJ Eichhorn, CC Eiswirth, S Emani, GA Ewald, RC Forde-McLean, MD Gelernt, DE Haines, CA Henrikson, JM Herre, B Herweg, L Ilkhanoff, LR Jackson, A Lala, R Lo, B London, BD Lowes, JA Mackall, V Malhotra, FA McGrew, S Murali, A Natale, KR Nilsson, J Okolo, MV Perez, RS Phang, R Ranjan, MY Rashtian, MJ Ross, SM Samii, T Shinn, MB Shoemaker, SA Strickberger, VN Tholakanahalli, A Tzur, PJ Wang, LT Younis
Publikováno v:
Circulation. Arrhythmia and Electrophysiology, 14(8):009591. LIPPINCOTT WILLIAMS & WILKINS
Background: Bucindolol is a genetically targeted β-blocker/mild vasodilator with the unique pharmacological properties of sympatholysis and ADRB1 Arg389 receptor inverse agonism. In the GENETIC-AF trial (Genotype-Directed Comparative Effectiveness T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b3b46d4e71ba0e2188b0ff7e480073
https://research.rug.nl/en/publications/e4da658b-c78f-4c9f-a6ea-3c34cd1b9426
https://research.rug.nl/en/publications/e4da658b-c78f-4c9f-a6ea-3c34cd1b9426
Autor:
Nancy K. Sweitzer, Mahdi Gharaibeh, Marion K. Slack, Brian L. Erstad, Christopher S. Lee, Ivo Abraham, Jason H. Karnes, Walter T. Klimecki, Nimer S. Alkhatib, Kenneth S. Ramos
Publikováno v:
American Journal of Cardiovascular Drugs. 21:205-217
Objective The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d622b6beeeacd2fb67f49ee23bb36085
https://doi.org/10.1007/s40256-020-00425-x
https://doi.org/10.1007/s40256-020-00425-x
Publikováno v:
JACC. Heart failure. 7(7):586-598
OBJECTIVES The purpose of this study was to compare the effectiveness of bucindolol with that of metoprolot sucdnate for the maintenance of sinus rhythm in a genetically defined heart failure (HF) population with atrial fibrillation (AF). BACKGROUND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___00893::6018fa4cfcf23122d3fee9a47507a335
https://hdl.handle.net/11370/338da4c8-6143-4a8e-8888-38e8a447575d
https://hdl.handle.net/11370/338da4c8-6143-4a8e-8888-38e8a447575d
Autor:
Béla Merkely, William T. Abraham, Michael R. Bristow, Laura L. Emery, Dirk J. van Veldhuisen, Michel White, Ian A. Carroll, Michiel Rienstra, William H. Sauer, Ryan G. Aleong, Leonard Ilkhanoff, Paul D. Ziegler, Jeff S. Healey, Christopher Dufton, Jonathan P. Piccini, Gordon Davis, Inder S. Anand, Yaariv Khaykin, Debra Marshall, Stuart J. Connolly, David P. Kao, Jerzy Krzysztof Wranicz, Vladimir Miloradovic, Steven K. Krueger, Stephen B. Wilton, Genetic-Af Trial Investigators, Felix Ayala-Paredes
Publikováno v:
JACC: Heart Failure. 7:586-598
Objectives The purpose of this study was to compare the effectiveness of bucindolol with that of metoprolol succinate for the maintenance of sinus rhythm in a genetically defined heart failure (HF) population with atrial fibrillation (AF). Background
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d876e7717a82a56d38cf2101928024f
https://doi.org/10.1016/j.jchf.2019.04.004
https://doi.org/10.1016/j.jchf.2019.04.004
Autor:
Brian L. Erstad, Ivo Abraham, Nancy K. Sweitzer, Jason H. Karnes, Nimer S. Alkhatib, Walter T. Klimecki, Mahdi Gharaibeh, Marion K. Slack, Kenneth S. Ramos
Publikováno v:
Expert Review of Precision Medicine and Drug Development. 3:319-329
Background: Sub-analyses from the BEST trial in heart failure (HF) indicated that Arg389 homozygote patients may respond to bucindolol. Bucindolol is currently being evaluated in Arg389 genotype pa...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f06e830241881156816a2a68e261f46
https://doi.org/10.1080/23808993.2018.1526079
https://doi.org/10.1080/23808993.2018.1526079
Autor:
Bruna Gazzi de Lima-Seolin, Jéssica Hellen Poletto Bonetto, Alessandra Eifler Guerra Godoy, Rafael Colombo, Isnard Elman Litvin, Rafael Oliveira Fernandes, Matheus Mittmann Hennemann, Paulo Cavalheiro Schenkel, Adriane Belló-Klein, Neelam Khaper, Rayane Brinck Teixeira, Alex Sander da Rosa Araujo
Publikováno v:
Biomedicine & Pharmacotherapy. 99:704-714
The aim of this study was to investigate the role of the ß-adrenergic blocker bucindolol on endothelial dysfunction and pulmonary vascular remodeling in rats with pulmonary arterial hypertension (PAH). Male Wistar rats were divided into four groups:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fd7cface1fc71192f86546a1c6f1604
https://doi.org/10.1016/j.biopha.2018.01.127
https://doi.org/10.1016/j.biopha.2018.01.127
Autor:
Palak Shah, Marco Metra
Publikováno v:
JACC: Heart Failure. 7:599-601
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e033c67c165c1b54db102aef8adf44e
https://doi.org/10.1016/j.jchf.2019.05.005
https://doi.org/10.1016/j.jchf.2019.05.005